London, UK – November 1, 2023 – Vantage Biosciences Ltd, a clinical-stage biotechnology company developing an oral small-molecule therapy for treatment of diabetic retinopathy, today announced its participation at the Ophthalmology Innovation Summit to take place in San Diego, California on December 1-2, 2023.

Dr Graeme Martin, CIO of ALSA Ventures, and board director at Vantage Biosciences, will present on VX-01 development as part of a dedicated session on novel oral treatments for diabetic retinopathy.

‍

Ophthalmology  Innovation Summit (OIS XIII)

Session: Spotlight  on Oral Therapies for Retina

Title: VX-01:  A Novel Oral Treatment for Non-Proliferative Diabetic Retinopathy

Day/Time:  Saturday, December 2, 2023, at 3:20pm PDT

About Vantage Biosciences

Vantage Biosciences is targeting the root cause of vision loss resulting from diabetes– the neuroinflammatory insult that precedes microangiopathy and leads to degeneration of the neurovascular unit of the eye.

Our mission is to enable patient access to disease modifying therapy for diabetic eye disease by developing drugs that intervene at the earliest point of disease biology.

For further information please visit https://www.vantage-biosciences.com/

Contact: enquiries@vantage-biosciences.com

‍